We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin.
- Authors
Mogyorósi, A.; Bradley, B.; Showalter, A.; Schubert, M. L.; Mogyorósi, A
- Abstract
Simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, is widely used to treat hyperlipidaemia. Although myalgias are recognized adverse effects, clinically significant elevations in serum creatine phosphokinase (CPK) levels are uncommon. We describe a case of rhabdomyolysis and acute renal failure associated with concomitant use of simvastatin and warfarin. Rhabdomyolysis and renal failure occurred 7 days after warfarin (5 mg day-1) was added to a chronic stable dose of simvastatin (20 mg day-1) and resolved abruptly after discontinuation of simvastatin. We recommend careful monitoring when warfarin is given to patients receiving simvastatin.
- Subjects
RHABDOMYOLYSIS; ACUTE kidney failure; WARFARIN; HYPERLIPIDEMIA treatment; DRUG side effects; DRUG therapy; ANTICOAGULANTS; CREATINE kinase; DRUG interactions; OXIDOREDUCTASES; SIMVASTATIN
- Publication
Journal of Internal Medicine, 1999, Vol 246, Issue 6, p599
- ISSN
0954-6820
- Publication type
journal article
- DOI
10.1046/j.1365-2796.1999.00610.x